Literature DB >> 14695994

Variety and complexity of chromosome 17 translocations in neuroblastoma.

Gudrun Schleiermacher1, Virginie Raynal, Isabelle Janoueix-Lerosey, Valérie Combaret, Alain Aurias, Olivier Delattre.   

Abstract

In neuroblastoma, the most frequent genetic alteration is gain of chromosome arm 17q, which arises from unbalanced translocations. To document these genetic events more precisely, we performed an extensive study of chromosome 17 breakpoints in 27 neuroblastoma cell lines by using a combination of fluorescence in situ hybridization mapping with BAC/PAC clones and allele analysis with polymorphic markers. All cases exhibited one or more unbalanced chromosome 17 translocations, and 15 distinct breakpoint regions could be mapped. This high variability indicates that gene fusion or disruption events are extremely unlikely to account for the underlying oncogenic role of these translocations. However, breakpoints were not randomly distributed, most of them mapping to the proximal part of 17q. As a result of translocations, all cell lines but one exhibited gain of the 53.5 Mb-->qter fragment, bordered proximally by the clone CTC-462L7. The most telomeric breakpoint, flanked by the clone RP11-443M10, defined the 70.9 Mb-->qter fragment as a region of additional gain. In addition to chromosome gains, loss of heterozygosity for the short arm of chromosome 17 was observed in close to half the cases. It was either related to a chromosome 17 monosomy or to a uniparental isodisomy. Finally, in cases with a single normal chromosome 17, we show that the parental origin of the translocated chromosome 17 can be either distinct or identical to that of the normal chromosome. Similarly, multiple translocations within the same cell line can either involve the same or different chromosome 17 homologues, indicating the likely absence of parental origin bias in the generation of these alterations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14695994     DOI: 10.1002/gcc.10313

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

Review 1.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

2.  Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis.

Authors:  Valentina Boeva; Stéphanie Jouannet; Romain Daveau; Valérie Combaret; Cécile Pierre-Eugène; Alex Cazes; Caroline Louis-Brennetot; Gudrun Schleiermacher; Sandrine Ferrand; Gaëlle Pierron; Alban Lermine; Thomas Rio Frio; Virginie Raynal; Gilles Vassal; Emmanuel Barillot; Olivier Delattre; Isabelle Janoueix-Lerosey
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

3.  PPM1D Is a Therapeutic Target in Childhood Neural Tumors.

Authors:  Jelena Milosevic; Diana Treis; Susanne Fransson; Gabriel Gallo-Oller; Baldur Sveinbjörnsson; Nina Eissler; Keiji Tanino; Kazuyasu Sakaguchi; Tommy Martinsson; Malin Wickström; Per Kogner; John Inge Johnsen
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

4.  Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

Authors:  G Schleiermacher; J Michon; I Huon; C Dubois d'Enghien; J Klijanienko; H Brisse; A Ribeiro; V Mosseri; H Rubie; C Munzer; C Thomas; D Valteau-Couanet; A Auvrignon; D Plantaz; O Delattre; J Couturier
Journal:  Br J Cancer       Date:  2007-06-19       Impact factor: 7.640

5.  Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line.

Authors:  Amparo López-Carrasco; Susana Martín-Vañó; Rebeca Burgos-Panadero; Ezequiel Monferrer; Ana P Berbegall; Beatriz Fernández-Blanco; Samuel Navarro; Rosa Noguera
Journal:  J Exp Clin Cancer Res       Date:  2020-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.